Tumour necrosis factor-alpha (TNF-α): The good, the bad and potentially very effective

Immunology and Cell Biology

Volumn 74, Issue 5, 1996, Pages 434-443

  Barbara, Jeffrey A J ^a   Van Ostade, Xaveer ^a   Lopez, Angel F ^a  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

Antineoplastic; Cytotoxicity; Inflammation; Receptors; Side effects; Signal transduction; TNF mutants

Indexed keywords

RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CYTOTOXICITY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOLECULAR CLONING; MUTANT; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; SIGNAL TRANSDUCTION; SUBCUTANEOUS DRUG ADMINISTRATION;

ARENA;

EID: 0029830209     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1038/icb.1996.73     Document Type: Review

References (107)

1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 1893; 105: 487-511.
2. Carswell WA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 1975; 72: 3666-70.
3. Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J. Exp. Med. 1985; 161: 984-95.
4. Beutler B, Greenwald D, Hulmes JD et al. Identity of tumour necrosis factor and the macrophage secreted factor cachectin. Nature 1985; 316: 552-4.
5. Pennica D, Nedwin GE, Hayflick JF et al. Human tumour necrosis factor: Precursor structure, expression and homology to lymphotoxin. Nature 1984; 312: 724-9.
6. Spies T, Morton CC, Nedospasov SA, Fiers W, Pious D, Strominger JL. Genes for the tumor necrosis factors α and β are linked to the human major histocompatibility complex. Proc. Natl Acad. Sci. USA 1986; 83: 8699-702.
7. Pociot F, Briant L, Jongeneel CV et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-α an TNF-β by human mononuclear cells: A possible link to insulin-dependent diabetes mellitus. Eur. J. Immunol. 1993; 23: 224-31.
8. Wilson AG, Gordon C, di Giovine FS et al. A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur. J. Immunol. 1994; 24: 191-5.
9. Fiers W, Brouckacrt P, Devos R et al. In: Molecular Biology of Homo Sapiens. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1986; 587-95.
10. Mohler KM, Sleath PR, Fitzner JN et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994; 370: 218-20.
11. Eck MJ, Sprang SR. The structure of tumor necrosis factor-α at 2.6 Å resolution: Implications for receptor binding. J. Biol. Chem. 1989; 264: 17 595-605.
12. Jones EY, Stuart DI, Walker NPC. Structure of tumour necrosis factor. Nature 1989; 338: 225-8.
13. Yamagishi J, Kawashima H, Matsuo N et al. Mutational analysis of structure-activity relationships in human tumour necrosis factor-alpha. Protein Engineering 1990; 3: 713-19.
14. Van Ostade X, Tavernier J, Prangé T, Fiers W. Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis. EMBO. J. 1991; 10: 827-36.
15. Hohmann H-P, Remy R, Brockhaus M, Van Loon APGM. Two different cell types have different major receptors for human tumor necrosis factor (TNFα). J. Biol. Chem. 1989; 264: 14927-34.
16. Brockhaus M, Schoenfeld H, Schlaeger H, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc. Nail Acad. Sci. USA 1990; 87: 3127-31.
17. Dembic Z, Loetscher H, Gublcr U et al. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine 1990; 2: 231-7.
18. Loetscher H, Pan Y-CE, Lahm H-W et al. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 1990; 61: 351-9.
19. Schall TJ, Lewis M, Koller KJ et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 1990; 61: 361-70.
20. Smith CA, Davis T, Anderson D et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990; 248: 1019-23.
21. Porteu F, Brockhaus M, Wallach D, Engelmann H, Nathan CF. Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. J Biol. Chem. 1991; 266: 18 846-53.
22. Hohmann H-P, Brockhaus M, Baeuerle PA, Remy R, Kolbeck R, Van Loon APGM. Expression of the types A and B tumor necrosis factor (TNF) receptors is independently regulated, and both receptors mediate activation of the transcription factor NF-κB. J. Biol. Chem. 1990; 265: 22 409-17.
23. Shalaby MR, Sundan A, Loetscher H, Brockhaus M, Lesslauer W, Espevik T. Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. J. Exp. Med. 1990; 172: 1517-20.
24. Mackay F, Loetscher H, Stueber D, Gehr G, Lesslauer W. Tumor necrosis factor α (TNF-α)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J. Exp. Med. 1993; 177: 1277-86.
25. Slowik MR, De Luca LG, Fiers W, Pober JS. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am. J. Pathol. 1993; 143: 1724-30.
26. Lewis M, Tartaglia LA, Lee A et al. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc. Natl Acad. Sci. USA 1991; 88: 2830-4.
27. Brouckaert P, Libert C, Everaerdt B, Fiers W. Selective species specificity of tumour necrosis factor for toxicity in the mouse. Lymphokine. Cytokine Res. 1992; 11: 193-6.
28. Engelmann H, Holtmann H, Brakebusch C et al. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J. Biol. Chem. 1990; 265: 14497-504.
29. Loetscher H, Gentz R, Zulauf M et al. Recombinant 55-kDa tumor necrosis factor (TNF) receptor: Stoichiometry of binding to TNFα and TNFβ and inhibition of TNF activity. J. Biol. Chem. 1991; 266: 18 324-9.
30. Pennica D, Kohr WJ, Fendly BM et al. Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: Evidence for tumor necrosis factor-α induced receptor aggregation. Biochem. 1992; 31: 1134-41.
31. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA Jr, Goeddel DV. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl Acad. Sci. USA 1991; 88: 9292-6.
32. Vandenabeele P, Declercq W, Vercammen D et al. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. J. Exp. Med. 1992; 176: 1015-24.
33. Loetscher H, Banner D, Brockhaus M et al. Structural aspects of TNF binding to its receptors: Evidence for segregated complexes. 4th Int. TNF Congress (May 2-6, 1992; Veldhoven). Eur. Cytokine Network 1992; 3: 136.
34. Banner DW, D'Arcy A, Janes W et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation. Cell 1993; 73:431-45.
35. Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science 1994; 264: 667-8.
36. Cosman D. A family of ligands for the TNF receptor superfamily. Stem Cells 1994; 12: 440-55.
37. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 1994; 76: 959-62.
38. Smith CA, Davis T, Wignall J et al. T2 open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor. Biochem. Biophys. Res. Commun. 1991; 176: 335-42.
39. Matthews N. Production of an antitumour cytotoxin by human monocytes. Immunology 1981; 44: 135-42.
40. Vassalli P. The pathophysiology of tumor necrosis factors. Annu. Rev: Immunol. 1992; 10: 411-52.
41. Spriggs DR, Deutsch S, Kufe DW. Genomic structure, induction, and production of TNF-α. In: Aggarwal BB, Vilcek J (eds). Tumor Necrosis Factors: Structure, Function, and Mechanism of Action. New York: Marcel Dekker 1992: 3-34.
42. Tracey KJ, Cerami A. Tumor necrosis factor: A pleiotropic cytokine and therapeutic target. Annu. Rew. Med. 1994; 45: 491-503.
43. Sugarman BJ, Aggarwal BB, Hass PE et al. Recombinant human tumor necrosis factor-α: Effects on proliferation of normal and transformed cells in vitro. Science 1985; 230: 943-5.
44. Vilcek J, Palombella VJ, Henriksen-DeStefano D et al Fibroblast growth-enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J. Exp. Med. 1986; 163: 632-43.
45. Fransen L, Van der Heyden J, Ruysschaert R, Fiers W. Recombinant tumour necrosis factor: Its effect and its synergism with interferon-γ on a variety of normal and transformed human cell lines. Eur. J. Cancer. Clin. Oncol. 1986; 22: 419-26.
46. Ruff MR, Gifford GE. Tumor necrosis factor. In: Pick (ed.) Lymphokines. Vol. 2. New York: Academic Press, 1981: 235-75.
47. Wallach D, Holtmann H, Engelmann H, Nophar Y. Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J. Immunol. 1988; 140: 2994-9.
48. Wong GHW. Elwell JH, Oberley LW, Goeddel DV. Manganous Superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 1989; 58: 923-31.
49. Klebanoff SJ, Vadas MA, Harlan JM et al. Stimulation of neutrophils by tumor necrosis factor. J. Immunol. 1986; 136: 4220-5.
50. Atkinson YH, Marasco WA, Lopez AF, Vadas MA. Recombinant human tumor necrosis factor-α: Regulation of N-formylmethionylleucylphenylalanine receptor affinity and function on human neutrophils. J Clin. Invest. 1988; 81: 759-65.
51. Camussi G, Bussolino F, Salvidio G, Baglioni C. Tumour necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J. Exp. Med. 1987; 166: 1390-404.
52. Atkinson YH, Murray AW, Krilis S, Vadas MA, Lopez AF. Human tumour necrosis factor-alpha (TNF-α) directly stimulates arachidonic acid release in human neutrophils. Immunology 1990; 70: 82-7.
53. Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA Jr. Activation of human polymorphonuclear neutrophil functions by interferon-γ and tumor necrosis factors. J. Immunol. 1985; 135: 2069-73.
54. Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc. Natl Acad. Sci. USA 1985; 82: 8667-71.
55. Bcvilacqua MP, Stengelin S, Gimbrone MA, Seed B. Endothelial leukocyte adhesion molecule 1: An inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 1989; 243: 1160-5.
56. Stricter RM, Kunkel SL, Showell HJ et al. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-α. LPS and IL-1β. Science 1989; 243: 1467-9.
57. Huber AR, Kunkel SL, Todd III RF, Weiss SJ. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science 1991; 254: 99-102.
58. Smith WB, Gamble JR, Clark-Lewis I, Vadas MA. Interleukin-8 induces neutrophil transendothelial migration. Immunology 1991; 72: 65-72,
59. Kuijpers TW, Hakkert BC, Hart MHL, Roos D. Neutrophil migration across monolayers of cytokine-prestimulated endothelial cells: A role for platelet-activating factor and IL-8. J. Cell. Biol. 1992; 117: 565-72.
60. Baggiolini M, Walz A, Kunkcl SL. Ncutrophil-activating pcptide-1/interleukin 8. a novel cytokine that activates neutrophils. J. Clin. Invest. 1989; 84: 1045-9.
61. Heller RA, Kronke M. Tumor necrosis factor receptor-mediated signaling pathways. J. Cell. Biol. 1994; 126: 5-9.
62. Obeid LM, Linardic CM, Karolak LA, Hannun YA. Programmed cell death induced by ceramide. Science 1993; 259: 1769-71.
63. Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem. 1994; 269: 3125-8.
64. Liu J, Mathias S, Yang Z, Kolesnick R. Renaturation and tumor necrosis factor-α stimulation of a 97-kDa ceramide-activatcd protein kinase. J. Biol. Chem. 1994; 269: 3047-52.
65. 2 is phosphorylated and activated by MAP kinase. Cell 1993; 72: 269-78.
66. 2 by p42 microtubulc-associated protein 2 kinase and protein kinase C. J. Biol Chem. 1993; 268: 1960-4.
67. Irvine RF. How is the level of free arachidonic acid controlled in mammalian cells? Biochem. J. 1982; 204: 3-16.
68. Hanahan DJ. Platelet activating factor: A biologically active phosphoglyceride. Annu. Rev. Biochem. 1986; 55: 483-509.
69. Darnay BG, Reddy SAG, Aggarwal BB. Physical and functional association of a serine-threonine protein kinase to the cytoplasmic domain of the p80 form of the human tumor necrosis factor receptor in human histiocytic lymphoma U-937 cells. J. Biol. Chem. 1994; 269: 19 687-90.
70. Darnay BG, Reddy SAG, Aggarwal BB. Identification of a protein kinase associated with the cytoplasmic domain of the p60 tumor necrosis factor receptor. J. Biol. Chem. 1994; 269: 20 299-304.
71. Beyaert R, Vanhaesebroeck B, Declercq W et al. Casein Kinase-1 phosphorylates the p75 tumor necrosis factor receptor and negatively regulates tumor necrosis factor signaling for apoptosis. J. Biol. Chem. 1995; 270: 23 293-9.
72. Rothc M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75kDa tumor necrosis factor receptor. Cell 1994; 78: 681-92.
73. Song HY, Dunbar JD, Zhang YX, Guo D, Donner DB. Identification of a protein with homology to hsp90 that binds the type 1 tumor necrosis factor receptor. J. Biol. Chem. 1995: 270: 3574-81.
74. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell 1995; 81: 495-504.
75. Stanger BZ, Leder P., Lee T-H., Kim E, Seed B. RIP: A novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 1995; 81: 513-23.
76. Jones AL, Selby P. Tumour necrosis factor: Clinical relevance. Cancer Surveys 1989; 8: 817-36.
77. Spriggs DR. Sherman ML, Frei III E, Kufe DW. In: Bonavida B, Granger G (eds) Tumour Necrosis Factor: Structure. Mechanism of Action, Role in Disease and Therapy. Basel: Karger, 1990; 233-9.
78. Alexander RB, Rosenberg SA. Tumor necrosis factor: Clinical applications. In: DeVita Jr VT, Hellman S, Rosenberg SA (eds) The Biologic Therapy of Cancer Philadelphia: JB Lippincott Co., 1991; 378-92.
79. Taguchi T, Sohmura Y. Clinical studies with TNF. Biotherapy 1991; 3: 177-86.
80. Saks S, Rosenblum M. Recombinant human TNF-α: Preclinical studies and results from early clinical trials. In: Aggarwal BB, Vilcek J (eds) Tumor Necrosis Factors: Structure, Function, and Mechanism of Action. New York: Marcel Dekker Inc, 1992; 567-87.
81. Spriggs DR, Yates SW. Clinical studies of tumour necrosis factor in the USA. In: Osawa T, Bonavida B (eds) Tumour Necrosis Factor: Structure Function Relationship and Clinical Application Basel: Karger, 1992; 275-84.
82. Fiers W. Tumour necrosis factor. In: Sims E (ed.) The Natural Immune System: Humoral Factors Oxford: IRL press, 1993; 65-119.
83. Lienard D, Ewalenko P, Delmotte J-J, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 1992; 10: 52-60.
84. Kettlehut IC, Fiers W, Goldberg AL. The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc. Natl Acad. Sci. USA 1987; 84: 4273-7.
85. Hauser GJ, McIntosh JK, Travis WD, Rosenberg SA. Manipulation of oxygen radical-scavenging capacity in mice alters host sensitivity to tumor necrosis factor toxicity but does not interfere with its antitumor efficacy. Cancer Res. 1990; 50: 3503-8.
86. Broner CW, Shenep JL, Stidham GL, Stokes DC, Hildner WK. Effects of scavengers of oxygen-derived free radicals on mortality in endotoxin-challenged mice. Crit. Care Med. 1988; 16: 848-51.
87. Satomi N, Sakurai A, Haranaka R, Haranaka K. Preventive effects of severals chemicals against lethality of recombinant human tumor necrosis factor. J Biol. Resp. Modif. 1988; 7: 54-64.
88. Tracey KJ, Beutler B, Lowry SF. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-4.
89. Braquet P, Touqui L, Shen TY, Vargaftig BB. Perspectives in platelet-activating factor research. Pharmacol. Rev. 1987; 39: 97-145.
90. Loetscher H, Stueber D, Banner D, Mackay F, Lesslauer W. Human tumor necrosis factor α (TNFα) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J. Biol. Chem. 1993; 268: 26350-7.
91. Van Ostade X, Vandenabeele P, Everaerdt B et al. Human TNF mutants with selective activity on the p55 receptor. Nature 1993; 361: 266-9.
92. Van Ostade X, Vandenabeele P, Tavernier J, Fiers W. Human tumour necrosis factor mutants with preferential binding to and activity on either the R55 or R75 receptor. Eur. J. Biochem. 1994; 220: 771-9.
93. Barbara JAJ, Smith WB, Gamble JR et al. Dissociation of TNF-α cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-α mutants. EMBO J. 1994; 13: 843-50.
94. Espevik T, Brockhaus M, Loetscher H, Nonstad U, Shalaby R. Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis receptor. J. Exp. Med. 1990; 171: 415-26.
95. Thoma B, Grell M, Pfizenmaier K, Scheurich P. Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses. J. Exp. Med. 1990; 172: 1019-23.
96. Brakebusch C, Nophar Y, Kemper O, Engelmann H, Wallach D. Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor. EMBO J. 11: 943-50.
97. Tartaglia LA, Goeddel DV. Tumor necrosis factor receptor signaling: A dominant negative mutation suppresses the activation of the 55-kDa tumor necrosis factor receptor. J. Biol. Chem. 1992; 267: 4304-7.
98. Heller RA, Song K, Fan N, Chang DJ. The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell 1992; 70: 47-56.
99. Menegazzi R, Cramer R, Patriarca P, Scheurich P, Dri P. Evidence that tumor necrosis factor a (TNF)-induced activation of neutrophil respiratory burst on biologic surfaces is mediated by the p55 TNF receptor. Blood 1994; 84: 287-93.
100. Paleolog EM. Delasalle S-AJ, Buurman WA, Feldmann M. Functional activities of receptors for tumor necrosis factor-α on human vascular endothelial cells. Blood 1994; 84: 2578-90.
101. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol. Today 1992; 13: 151-3.
102. Grell M, Douni E, Wajant H et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83: 793-802.
103. Pfeffer K, Matsuyama T, Kündig TM et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993; 73: 457-67.
104. Rothe J, Lesslauer W, Lötscher H et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993; 364: 798-802.
105. Erickson SL, de Sauvage FJ, Kikly K et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994; 372: 560-3.
106. Van Zee KJ, Stackpole SA, Montegut WJ et al. A human tumor necrosis factor (TNF) a mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon. J. Exp. Med. 1994; 179: 1185-91.
107. Bemelmans MHA, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J. Immunol. 1993; 150: 2007-17.